These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 36055113)

  • 1. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
    Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
    Zhang Q; Yang C; Gao X; Dong J; Zhong C
    Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
    AmeliMojarad M; AmeliMojarad M; Cui X
    Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy.
    Power Coombs MR; Hoskin DW
    Methods Mol Biol; 2020; 2111():161-173. PubMed ID: 31933207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
    Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
    Filippone A; Lanza M; Mannino D; Raciti G; Colarossi C; Sciacca D; Cuzzocrea S; Paterniti I
    Cancer Immunol Immunother; 2022 Sep; 71(9):2067-2075. PubMed ID: 35092481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy.
    Yin S; Chen Z; Chen D; Yan D
    Theranostics; 2023; 13(5):1520-1544. PubMed ID: 37056572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
    Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
    Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.
    Yan T; Yu L; Shangguan D; Li W; Liu N; Chen Y; Fu Y; Tang J; Liao D
    Int Immunopharmacol; 2023 Feb; 115():109638. PubMed ID: 36587500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists.
    Broggi G; Angelico G; Farina J; Tinnirello G; Barresi V; Zanelli M; Palicelli A; Certo F; Barbagallo G; Magro G; Caltabiano R
    Pathol Res Pract; 2024 Feb; 254():155144. PubMed ID: 38277747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
    Ho M; Bonavida B
    Cells; 2024 May; 13(10):. PubMed ID: 38786085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
    Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
    Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.